



Center for Biomedical Innovation

Contact: Cheryl Mottley

Center for Biomedical Innovation Announces Founding Consortium Members

(Cambridge MA- June 16, 2006) The MIT Center for Biomedical Innovation (CBI), a collaborative “think and do” tank where academic, industry and government experts work together to transform health care innovation and delivery throughout the world, today announced its Founding Consortium Members.

The six Founding sponsors are companies in the biopharmaceutical industry and include:

Altana Pharma
AstraZeneca Pharmaceuticals
Bayer AG
Eli Lilly & Co
Gene Logic, Inc.
Merck & Company

“We are grateful to these companies for their support and partnership in advancing the mission of CBI,” said Frank Douglas, MD, PhD, Executive Director of the Center. “Their commitment to collaboration and innovation in the biopharm industry will enable us to move forward on an ambitious education and research agenda that we believe will transform the industry, providing solutions that enhance the safety, development, distribution and commercial value of pharmaceuticals.”

CBI provides its Consortium Members and partners the opportunity to collaborate at the forefront of biomedical innovation. Participating organizations benefit from research- and education-based collaboration with other world-class industry, academic and government thought leaders.

More information about sponsorships with the Center for Biomedical Innovation can be obtained on the CBI website, <http://web.mit.edu/cbi> or by contacting the Center at (617) 253-0183.

About The Center for Biomedical Innovation

The MIT Center for Biomedical Innovation (CBI) was formed in 2005. CBI is a collaboration of the MIT Schools of Engineering, Management, and Science and the Harvard-MIT Division of Health Sciences & Technology (HST). CBI’s goal is to create a “safe haven” in which thought leaders across the biomedical spectrum - from medical researchers to federal regulators and payers, to experts in finance and marketing - are able to conduct pre-competitive research and catalyze industry-wide adoption of the resulting solutions.

At the Center, academic, industry and government experts work together to transform health care innovation and delivery throughout the world. Led by Frank L. Douglas, Ph.D., M.D., CBI delivers high impact, systemic solutions across the entire biomedical value chain, enhancing safety, productivity and commercial value. Our research focuses on four action areas: Safety Assessment, R&D Redesign, Manufacturing and Distribution Systems, and Economic, Financial and Risk Management.

Web: <http://web.mit.edu/cbi/>

Email: cbi@mit.edu

Phone: 617-253-0257

Fax: 617-253-0687

Mailing Address:

MIT Center for Biomedical Innovation
77 Massachusetts Avenue (NE20-382)
Cambridge, MA 02139-4307